Novartis AG
Novartis AG (NVS) Financial Performance & Income Statement Overview
Explore the financials of Novartis AG (NVS), including yearly and quarterly data on income, cash flow, and balance sheets.
Novartis AG (NVS) Income Statement & Financial Overview
Explore comprehensive income reports for Novartis AG NVS, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $13.62B | $13.56B | $13.17B | $12.87B |
| Cost of Revenue | $3.23B | $3.32B | $3.23B | $3.17B |
| Gross Profit | $10.39B | $10.23B | $9.94B | $9.70B |
| Gross Profit Ratio | $0.76 | $0.75 | $0.75 | $0.75 |
| R&D Expenses | $2.37B | $2.84B | $2.39B | $2.37B |
| SG&A Expenses | $3.06B | $3.50B | $3.13B | $3.09B |
| Operating Expenses | $5.73B | $6.70B | $6.31B | $5.68B |
| Total Costs & Expenses | $8.96B | $10.03B | $9.54B | $8.86B |
| Interest Income | $0.00 | $291.00M | $26.00M | $246.00M |
| Interest Expense | $0.00 | $275.00M | $264.00M | $246.00M |
| Depreciation & Amortization | $1.09B | $1.63B | $1.97B | $1.16B |
| EBITDA | $5.75B | $5.19B | $5.61B | $5.25B |
| EBITDA Ratio | $0.42 | $0.38 | $0.43 | $0.41 |
| Operating Income | $4.66B | $3.53B | $3.63B | $4.01B |
| Operating Income Ratio | $0.34 | $0.26 | $0.28 | $0.31 |
| Other Income/Expenses (Net) | -$256.00M | -$245.00M | -$242.00M | -$173.00M |
| Income Before Tax | $4.41B | $3.29B | $3.38B | $3.84B |
| Income Before Tax Ratio | $0.32 | $0.24 | $0.26 | $0.30 |
| Income Tax Expense | $798.00M | $465.00M | $200.00M | $595.00M |
| Net Income | $3.61B | $2.82B | $3.19B | $3.25B |
| Net Income Ratio | $0.26 | $0.21 | $0.24 | $0.25 |
| EPS | $1.83 | $1.40 | $1.58 | $1.60 |
| Diluted EPS | $1.82 | $1.39 | $1.57 | $1.59 |
| Weighted Avg Shares Outstanding | $1.97B | $1.99B | $2.01B | $2.04B |
| Weighted Avg Shares Outstanding (Diluted) | $1.98B | $2.004B | $2.03B | $2.05B |
Over the last four quarters, Novartis AG achieved steady financial progress, growing revenue from $12.87B in Q2 2024 to $13.62B in Q1 2025. Gross profit stayed firm with margins at 76% in Q1 2025 versus 75% in Q2 2024. Operating income totaled $4.66B in Q1 2025, maintaining a 34% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $5.75B. Net income rose to $3.61B, with EPS at $1.83. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan